Corpus Intelligence IC Memo — UNIVERSITY OF VIRGINIA MEDICAL CENTE 2026-04-26 06:56 UTC
IC Memo — UNIVERSITY OF VIRGINIA MEDICAL CENTE
Investment Committee Memorandum | VA | 665 beds | Grade B | EBITDA uplift $174.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF VIRGINIA MEDICAL CENTE

CCN 490009 | nan, VA | 665 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF VIRGINIA MEDICAL CENTE is a 665-bed large academic medical center in nan, VA with $2.37B in net patient revenue and a 1.1% operating margin. The hospital serves a payer mix of 23.8% Medicare, 7.3% Medicaid, and 68.9% commercial.

Thesis: Undervalued. Our ML models identify $174.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.1% to 8.4% (+736bps).

Net Revenue HCRIS$2.37B
Current EBITDA COMPUTED$25.0M
Operating Margin COMPUTED1.1%
Occupancy HCRIS73.9%
Revenue / Bed COMPUTED$3.6M
Net-to-Gross HCRIS30.8%
Distress Probability ML41.8%

2. Market Context & Competitive Position

111
VA Hospitals
4.4%
State Median Margin
12
Comparable Hospitals

VA has 111 Medicare-certified hospitals with a median operating margin of 4.4%. The target's margin of 1.1% places it below the state median. Among 12 size-comparable peers (332-1330 beds), the median margin is 1.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (332-1330), prioritizing same-state peers. 12 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF VIRGINIA MEDICAL (Target)VA665$2.37B1.1%
INOVA FAIRFAX HOSPITALVA860$2.41B20.5%
VCU HEALTH SYSTEM MCV HOSPITALVA842$2.26B0.3%
CARILION MEDICAL CENTERVA637$1.46B-11.3%
SENTARA NORFOLK GENERAL HOSPITVA472$1.34B4.9%
CJW MEDICAL CENTERVA612$1.00B32.8%
RIVERSIDE REGIONAL MEDICAL CENVA379$963.3M-20.1%
WINCHESTER MEDICAL CENTERVA455$694.7M-5.8%
ST. MARYS HOSPITALVA363$688.9M13.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $174.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$49.8M+210bp18mo
Cost to Collect4.5%2.5%$47.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$46.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$28.8M+122bp9mo
Clean Claim Rate88.0%96.0%$1.5M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$49.8M
Cost to Collect
$47.4M
Denial Rate Reduction
$46.9M
A/R Days Reduction
$28.8M
Clean Claim Rate
$1.5M
Total EBITDA Uplift$174.5M
Current EBITDA$25.0M
+ RCM Uplift+$174.5M
Pro Forma EBITDA$199.5M
Current Margin1.1%
Pro Forma Margin8.4%
WC Released (1x)$90.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$38.5M$1.91B49.66x118.4%
Base (11x exit)10.0x11.0x$38.5M$2.11B54.95x122.8%
Bull Case9.0x11.0x$34.6M$2.70B78.06x139.1%
Bull (12x exit)9.0x12.0x$34.6M$2.96B85.45x143.4%
Bear Case11.0x10.0x$42.3M$1.02B24.23x89.2%
Bear (11x exit)11.0x11.0x$42.3M$1.14B26.98x93.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 12 hospitals with 332-1330 beds
  • Same-state prioritization (n=13)
  • Comp margins: P25=-2.8% / P50=1.8% / P75=16.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.